Asthma

This study indicated the potential of PDLs as a strategy for those that have HDHP-HSAs to address both patient access and affordability of asthma care.

New research on the effects of the Canadian wildfires on asthma syndrome in patients sheds light on the downstream effects of ecological disaster on regions outside of those affected.

These findings highlight the potential of dupilumab treatment in improving lung function among children that are shown to have uncontrolled, moderate-to-severe type 2 asthma.

These new findings may help shape both the design and the use of an educational intervention on technology-based inhaler techniques for patients with pediatric asthma.

This new analysis indicated that on-treatment remission of asthma could be viewed as a realistic goal for individuals with severe asthma who are treated with biologics.

This new data suggests substantial effects of socio-economic factors in the early stages of a child’s life and their impact on health equity for pediatric asthma.

These new findings suggest the COMSA parameters may have applicability for standardizing observational studies’ results for pediatric patients with asthma.

Raffi Tachdjian, MD, MPH, FAAAAI, FACAAI; Dareen D. Siri, MD, FAAAAI, FACAAI; Nicole Chase, MD, FAAP, FACAAI, FAAAAI; and Andrew White, MD, give final thoughts on asthma management, considering the current treatment landscape.

Experts outline biomarkers to measure asthma, highlighting eosinophil count and fractional exhaled nitric oxide levels.

Experts discuss the use of biologic treatment in asthma by primary care physicians vs pulmonology specialists as well as overcoming barriers to biologic use through patient and physician education.

Experts comment on switching from 1 biologic treatment to another, as well as combining biologics with steroids or other treatments in asthma.

Andrew White, MD, discusses choosing the right biologic for patients with severe asthma, considering factors such as asthma comorbidities as well as patient preference.

Dareen D. Siri, MD, FAAAAI, FACAAI, reviews the efficacy and safety of dupilumab for the treatment of asthma, as well as which patients are good candidates for dupilumab.

Nicole Chase, MD, FAAP, FACAAI, FAAAAI, provides an overview of the difference between single and dual inhibition of interleukins, focusing on dupilumab as a dual inhibitor for asthma treatment.

Experts discuss the use of biologic agents to manage asthma and describe the mechanisms of action of different biologics.

Medical expert highlights the risk of overuse of oral corticosteroids in the management of asthma and reviews alternative treatment options.

A new study highlights the benefits of using the hypertonic saline test to determine the appropriate dose of inhaled corticosteroids for managing asthma in children.

Andrew White, MD, reviews the definition of difficult-to-treat or severe asthma as outlined in the GINA (Global Initiative for Asthma) guidelines.

Experts discuss the process of choosing a treatment plan for patients with severe allergic or eosinophilic asthma.

Andrew White, MD, provides an overview of the asthma treatment landscape, focusing on inhaled and oral corticosteroids, as well as biologic and nonbiologic agents.

Diagnosis, evaluation, and treatment recommendations for pregnant individuals with asthma follow similar principles as for nonpregnant patients, but investigators address specific challenges.

Amid mass poor air quality exposure due to ongoing Canadian wildfires, Lungcast reviews air quality index, signs and symptoms of acute and long-term poor air exposure, high-risk patient populations, and the concerning future of particle pollution exposure.

Dr. Jean-Pierre Llanos Ackert and Dr. Chris Ambrose discuss the latest data on the breakthrough biologic for severe asthma.

Investigators Dr. Jean-Pierre Llanos Ackert and Dr. Chris Ambrose share insight on the efficacy of tezepelumab in severe, uncontrolled asthma, and baseline predictors of enhanced response which support tezepelumab as a promising biologic treatment option.

Lungcast hits the road, as the director of pulmonary and critical care medicine at University of Vermont joins to discuss ATS 2023 headlines and the Airways Clinical Research Network.